DIAGNOSIS OF CARDIAC ISCHEMIA WITH UNBOUND FFA

描述：(申请人摘要)这项建议的长期目标是 建立一种简便的血液检测方法用于心肌梗死的早期诊断 缺血症。缺血性心脏病是美国人死亡的主要原因 各州。目前的诊断方法要么不可靠，要么复杂，而且 很贵的。心脏标记物检测可靠，但不能检测到缺血 请注意。相比之下，我们提出的诊断方法，血清的测量 非绑定FFA(FFAU)，包括简单、廉价、几乎瞬时的 和易于获取的测量，具有很高的揭示 缺血事件。在拟议的第一阶段研究中，我们将确定血浆 用我们的ADIFAB荧光法测量的FFAU水平提供了一个早期的 大鼠心肌缺血的指示物。如果，正如我们从预赛中所期待的那样 研究表明，血浆FFAU水平在几分钟内就会上升到非常高的水平 在缺血损伤后，我们应该能够利用大鼠模型 帮助确定此化验的特征，为第二阶段做准备 在人类病人身上进行试验。 建议的商业应用： 如果成功，这项研究将证明游离脂肪酸(FFAU) 提供最早和最灵敏的基于血液分析的心肌检测方法 缺血症。如果得到随后的第二阶段和第三阶段试验的支持，我们预计在 与一种小型、廉价的单一用途荧光仪相结合，这种分析方法将 用于提供心肌缺血的最早指示。这项化验是基于 我们的专利方法是唯一报道的测量FFAU的方法，因此 确保了相当大的商业应用。

DESCRIPTION: (Applicant's abstract) The long term goal of this proposal is to develop a simple blood-based assay for the early diagnosis of myocardial ischemia. lschemic heart disease is the major cause of death in the United States. Current methods of diagnosis are either unreliable or complex and expensive. Cardiac marker assays reliably detect necrosis but not ischemia per se. In contrast, the diagnostic method we propose, the measurement of serum unbound FFA (FFAu), involves a simple, inexpensive, virtually instantaneous, and readily accessible measurement that has high potential for revealing the ischemic event. In the proposed Phase I studies we will determine if plasma FFAu levels, measured with our ADIFAB fluorescence method, provide an early indicator of cardiac ischemia in the rat. If, as we expect from preliminary studies, plasma levels of FFAu rise to very high levels within minutes following the ischemic insult, then we should be able to use the rat model to help define the characteristics of this assay in preparation for a Phase II trial in human patients. PROPOSED COMMERCIAL APPLICATION: If successful this research would demonstrate that unbound free fatty acids (FFAu) provide the earliest and most sensitive blood-assay based measure of myocardial ischemia. If supported by subsequent phase II and III trials, we would expect, in conjunction with a small, inexpensive single purpose fluorometer, that this assay would be used to provide the earliest indication of myocardial ischemia. This assay is based on our patented method which is the only reported method for measuring FFAu, thereby ensuring considerable commercial application.